Japanese chemical firm Toray partners with QB3@953 to pursue breakthroughs in treatment of neurological diseases 

QB3@953, the Bay Area's premier life science incubator, welcomes Japan's chemical giant Toray as its newest partner. The arrangement offers Toray the opportunity to nurture its budding pharmaceutical enterprise while bringing new expertise and trans-Pacific relationships to QB3@953's research community.

Please read full Press Release
How This AgTech Startup Is Giving Farmers Insight Into Their Soil's Health

Trace Genomics was featured at Forbes. Full Article
Forbes interview with Trace Genomics founders Diane Wu and Poornima Parameswaran
AMGEN and QB3@953 announce winners of the AMGEN GOLDEN TICKETS

Two Diagnostic Companies Will Receive Lab Space and Other Benefits at San Francisco Life Sciences Incubator.

Darmiyan and Enable Biosciences have won the Amgen Golden Ticket at QB3@953. Each company receives one year of lab space at the QB3@953 life sciences incubator, additional facility benefits and connections to Amgen's scientific and business leaders to help advance their scientific programs. The Amgen Golden Ticket program was launched by Amgen in 2015 to assist early-stage life sciences companies in their efforts to advance biology and technologies for the benefit of patients suffering from serious illnesses.
Please read full Press Release
Lunch Seminar: August 10, 12:00 - 1:00 PM
Corporate and Patent Law Boot Camp
Elton Satusky and Ali Alemozafar
Wilson Sonsino Goodrich & Rosati


Elton Satusky and Ali Alemozafar of Wilson Sonsini will present on important corporate and intellectual property topics for startups, including corporate formation and venture financing, and strategies for protecting intellectual property.

Lunch Seminar: August 11, 12:00 - 1:00 PM
Targeting KRAS for cancer therapy
Frank McCormick, PhD, FRS
UCSF Helen Diller Family Comprehensive Cancer Center



KRAS proteins play a major role in human cancer. To target the KRAS protein directly, we have used tethering to identify compounds that covalently bind at two key residues, one which affects KRAS membrane localization, and another at a site unique to KRAS amongst other RAS proteins. We have also screened for molecules that cause allosteric changes in KRAS detected by a novel biophysical technique called Second Harmonic Generation. Dr. McCormick will discuss how these approaches are being developed and prospects for treating cancer using these, and other, KRAS inhibitors.

Frank McCormick, PhD, FRS, is a Professor at the UCSF Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated and led drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. Sorafenib is being tested in multiple indications worldwide.

Lunch Seminar: August 17, 12:00 - 1:00 PM
Chromotography Resin for 21st Century protein purification
Pierre Tremblay, PhD
GE Healthcare



This presentation will cover the latest GEHC chromatography resin portfolio. We will discuss the advantages of the modern bases matrices in the context of improving selectivity and throughput as it relates to process economy. We will also present and discuss approaches to resolve some purification challenges using both PreDictor plates (filter plates) and columns formats.

Pierre Tremblay has been with GE Healthcare for 15 years but started in protein purification as a graduate student. He supported and then lead the BioProcess courses in the GE portfolio, delivering custom courses at industry and academic sites.

Celebration: August 31, 2:00 -3:30pm
An Afternoon Tea Party for the Awesome 3 from the Magnificent 7!


From common-but-stubborn ailments like acne to the future of gene therapy or personalized cancer care, the breadth of biotech innovation happening in the Bay Area is vast. All told, the California Life Sciences Association estimates that the sector accounts for some 68,300 jobs in the region and nearly $1 billion in annual venture capital investment.

To capture a snapshot of the work under way, the Business Times selected seven young scientists and entrepreneurs spanning established drugmakers, startups and academia. Though their interests and backgrounds are varied, they all have one thing in common: each is poised to make a major impact on the future of life sciences. 

Read the complete article at BizJournals